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Abstract
Cancer biomarkers facilitate screening and early detection but are known for only a few cancer types. We demonstrated the
principle of inducing tumors to secrete a serum biomarker using a systemically administered gene delivery vector that
targets tumors for selective expression of an engineered cassette. We exploited tumor-selective replication of a
conditionally replicative Herpes simplex virus (HSV) combined with a replication-dependent late viral promoter to achieve
tumor-selective biomarker expression as an example gene delivery vector. Virus replication, cytotoxicity and biomarker
production were low in quiescent normal human foreskin keratinocytes and high in cancer cells in vitro. Following
intravenous injection of virus .90% of tumor-bearing mice exhibited higher levels of biomarker than non-tumor-bearing
mice and upon necropsy, we detected virus exclusively in tumors. Our strategy of forcing tumors to secrete a serum
biomarker could be useful for cancer screening in high-risk patients, and possibly for monitoring response to therapy. In
addition, because oncolytic vectors for tumor specific gene delivery are cytotoxic, they may supplement our screening
strategy as a ‘‘theragnostic’’ agent. The cancer screening approach presented in this work introduces a paradigm shift in the
utility of gene delivery which we foresee being improved by alternative vectors targeting gene delivery and expression to
tumors. Refining this approach will usher a new era for clinical cancer screening that may be implemented in the developed
and undeveloped world.
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Introduction
Early cancer detection is vital to improve cure rates because
cancer stage predicts prognosis. Cancer-associated blood biomark-
ers have been identified in a few cancers such as prostate specific
antigen (PSA) in prostate cancer and alpha fetoprotein in some liver
and germline cancers. Biomarkers have not been identified for most
pediatric cancers and many adult cancers. New innovations in
systemic gene transferraise the prospectof selectively delivering and
activating genes encoding easily detectable biomarkers into tumor
cells that do not produce known serum biomarkers. We sought to
develop a prototypical cancer screening strategy whereby genetic
information encoding a universal serum biomarker for cancer
would be injected into a patient systemically, delivered to and
expressed within tumor cells in a tumor-selective manner. Tumors
would effectively be forced to secrete a serum biomarker, which
could then be measured in the blood or urine as a screening test
while tumor-free patients would show no or only low levels of
biomarker following systemic administration of the gene delivery
vector (Fig. 1a).
Exogenously administered gene-encoded biomarkers require
tumor-targeted gene delivery and/or expression. Targeting small
molecules and particles to tumors can be achieved by passive
Enhanced Permeability and Retention (EPR) [1,2,3], ligand-
guided active targeting [4,5,6,7], tumor microenvironment-
dependent targeting [8,9,10], or a combination of each [11].
Viruses are naturally occurring nanoparticles optimized to deliver
genetic information into target cells. The major advantage of
viruses over non-viral vectors for DNA delivery is their inherent
predilection for replication in tumors and consequent amplifica-
tion of signal.
The Herpes Simplex Virus (HSV) type 1 is a model gene
delivery vector because it can infect a wide range of human cell
types, transduce both dividing and quiescent cells efficiently, be
engineered to express transgene products, accept transgenes
driven by heterologous or homologous promoters, is epigenomic,
has scalable production, and can safely be controlled with antiviral
drugs [12]. Selective mutations in HSV genes confer cancer-
selective viral replication. Mutation in the HSV genes encoding
the ribonucleotide reductase large subunit (ICP6/UL39) and the
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tumors [13,14,15,16] and have been shown to be safe in clinical
trials. Activation of the strict late viral UL38 gene is dependent
upon preceding sequential activation of immediate early and early
viral genes and cellular transcription factors [17] and the UL38
promoter (UL38p) has been demonstrated to be selectively
activated in cancer cells in the context of replication competent
c134.5
2/2 HSV mutants [18]. The dependence of late gene
expression upon activation by early genes makes UL38p a strong
candidate for delivery of transgenes to cancer cells with selective
expression in the context of a double mutant HSV lacking ICP6
and c134.5.
We developed an HSV as an exemplar gene delivery vector for
inducing biomarker secretion selectively from tumors. Others have
incorporated genes encoding secretable biomarkers to oncolytic
viruses as reporters for virus activity [19,20,21,22] and gene
cassettes for non-invasive monitoring viral delivered genes [23].
Sodium-iodide symporter genes encoded in oncolytic viruses also
facilitate nuclear medicine imaging and treatment in infected
tumors [24,25]. Recently, Gaussia luciferase (GLuc) was identified
and developed as a powerful new reporter molecule [26] that is
readily secreted from cells making it useful for both in vitro and in
vivo applications where expression kinetics are of interest. We
employed GLuc as a sample biomarker for this proof of principle
because GLuc is 1000 times brighter than other luciferases, is
more sensitive than secretable alkaline phosphatase, and is
detectable in blood and urine in vivo [27,28]. Using a directed
recombination approach [29], we engineered an HSV mutant,
rQ-M38G, with GLuc under the control of the late viral promoter
UL38 (Fig. 1b).
We sought to evaluate our engineered viral gene delivery vector
in animal models for several different tumor types formed different
locations: intraperitoneal, subcutaneous, intramuscular and ortho-
topic intrarenal tumors. Following systemic injection of our gene
delivery vector (rQ-M38G) into the blood of tumor-bearing mice,
we observed rQ-M38G producing cancer cell-dependent cytotox-
icity and biomarker production. We also noted several instances
where rQ-M38G was able to force microscopic tumor burdens to
produce detectable blood biomarker. These experimental trials
demonstrated the principle of detecting tumors by forcing them to
express a secretable biomarker.
Results
In vitro characterization of mutant HSV rQ-M38G
rQ-M38G-mediated GLuc transduction, replication and cyto-
toxicity were tested by infecting a range of cell types with various
virus concentrations and assessing GLuc levels in culture media
(Fig. 2a, Fig. S1), virus genome copy number (Fig. 2b, Fig. S2) and
cytotoxicity (Fig. 2c, Fig. S3) on days 2, 4, and 6 after infection.
Cell replication-dependent cytotoxicity was observed in replicating
human foreskin keratinocytes (HFK-r) while cytotoxicity was
attenuated or absent in differentiated/quiescent human foreskin
keratinocytes (HFK-q) (Fig. S3). Vero, an African green monkey
kidney cell line that is known for permissive HSV replication,
showed high GLuc expression and rQ-M38G replication following
low dose rQ-M38G infection (MOI=0.001, 1 virus per 1000
cells).
We assessed transgene expression, virus replication and
cytotoxicity following rQ-M38G infection of 5 human tumor cell
Figure 1. Overall strategy for exogenous cancer biomarkers. (a) Steps for cancer screening strategy are as follows: 1) Cancer-targeting Herpes
Simplex Virus (HSV) is injected systemically. 2) Engineered HSV selectively replicates in tumors while being cleared from healthy non-cancerous
tissues. 3) Biomarker is selectively produced in tumors. 4) Blood samples are collected and analyzed for biomarker levels. 5) Serum levels of
exogenously delivered biomarker are higher in tumor bearing mice than healthy tumor-free mice. (b) Gene maps for wild-type HSV and novel
recombinant rQ-M38G.
doi:10.1371/journal.pone.0019530.g001
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expression, virus replication and cytotoxic susceptibility similar to
Vero cells. Osteomet (Osteosarcoma), STS26T_dsRed (MPNST),
and S462.TY (MPNST) each demonstrated lower sensitivity in all
three assays. Finally, we assessed cytotoxicity in 3 well established
mouse tumor models derived from a C57/Bl6 background (Fig.
S3) and several spontaneous murine thyroid or small cell lung
tumor lines generated by a collaborator (data not shown). HGF116
(rhabdomyosarcoma) was the only cell line showing any
measurable cytotoxicity, but only at a high virus dose (MOI=1,
1 infectious virus per cell). These data identified SK-NEP_Luc as a
prime target for in vivo screening using rQ-M38G while other
human tumor cell lines were predicted to be less amenable to
screening with rQ-M38G.
Systemic administration of rQ-M38G to identify tumor
presence
We tested the suitability of rQ-M38G as a gene delivery
vector to force tumor-specific secretion of a biomarker following
systemic administration of rQ-M38G in mice with and without
tumors. Eleven mice were injected orthotopically with 10
6 SK-
NEP_Luc cells into their renal subcapsule. Tumor-implanted
mice and control tumor-free mice were subsequently injected
intravenously (i.v) with 1.2610
7 pfu of rQ-M38G 5 weeks after
tumor implantation. On days 1, 4 and 7 following virus injection
mice were imaged to identify firefly luciferase-positive tumors
and blood samples were collected by retro-orbital eye bleed and
assayed for serum GLuc (Fig. 3a). In vivo imaging identified 10
out of 11 mice which received tumor cell injections had formed
tumors (Fig. 3b). One mouse (#9) never formed a tumor and
one mouse (#11) had a tumor that was scarcely detectable. In
all mice where tumor burden was apparent (9 out of 11), serum
GLuc levels were 15- to 440-fold higher than tumor-free mice,
whereas serum GLuc from the other two mice remained below
control mouse serum GLuc levels (Fig. 3). Therefore, rQ-M38G
administered systemically to induce biomarker production
resulted in a detection sensitivity of 90% for SK-NEP_Luc-
bearing mice. Similar results were for tumors in different
anatomical sites (Fig. S4).
To determine the location of rQ-M38G in tissues following i.v.
injection and confirm that the serum GLuc signal was being
expressed from tumors and not normal organs, organs were
harvested from mice 7 days after virus infection and subjected to
immunofluorescence for GFP expression and quantitative PCR for
virus genomes. Only tumors demonstrated GFP expression in both
control (data not shown) and experimental mice (Fig. 4a) injected
systemically with rQ-M38G. Quantitative PCR for virus genome
copies reflected the same distribution of virus in tumor-bearing
mice as was seen with GFP expression where virus copies were at
least 2100–fold higher in the tumors than healthy tissues (Fig. 4b).
Immunofluorescence and qPCR indicate that virus infection
predominated in the tumor while being minimal in healthy
tissues. Therefore, systemically administered rQ-M38G success-
fully identified the presence of SK-NEP_Luc tumors by forcing
tumors to produce a secretable biomarker. We demonstrated
similar findings in tumor models that are less susceptible to virus
infection including models of malignant peripheral nerve sheath
tumors (in both subcutaneous and intraperitoneal locations) and
osteosarcoma (Figures S5, S6, S7).
Induction of GLuc expression in tumors by intratumoral
virus injection
A clear difference was observed between SK-NEP_Luc and the
three other tumor models tested which each showed lower in vitro
cytotoxicity and GLuc expression coupled with lower biomarker
expression in vivo. To identify whether delivering larger doses of
virus to tumors could increase in vivo biomarker expression, we
administered rQ-M38G directly into tumors by intratumoral
injection in models of S462.TY and Osteomet.
Mice bearing subcutaneous flank Osteomet tumors greater than
200 mm
3 were injected with 1.9610
5 pfu of virus. Blood samples
were collected and analyzed for GLuc at each time point (Fig. S7a)
while two mice were sacrificed at each time point and analyzed for
viral genomic copies by qPCR (Fig. S7b). Serum GLuc levels in
blood from mice bearing tumors injected with rQ-M38G was
higher than GLuc levels in control uninfected mice, and increasing
GLuc over time traced a profile similar to viral copy number in
tumors. Despite a 4000-fold genomic amplification in tumors,
Figure 2. Differential sensitivity of cell lines to virus infection. (a) Gaussia luciferase (GLuc) transgene expression, (b) virus replication, and (c)
cytotoxicity following infection of Vero cells and a panel of human tumor cell lines with rQ-M38G (MOI=0.001).
doi:10.1371/journal.pone.0019530.g002
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Intratumoral injection with 8610
3 pfu or 8610
7 pfu of virus was
repeated in S462.TY tumors when tumors were larger than
500 mm
3. Four days after i.t. injection serum GLuc levels were
assayed as plotted in Fig. S8. All mice receiving intratumoral
injection of virus demonstrated higher GLuc levels than tumor-
free controls without a significant difference in GLuc concentra-
tion between the low dose and 10,000-fold high virus dose,
suggesting saturation at the low dose (at least via the intratumoral
route).
Biomarker sensitivity
Small animal models used to detect minimal tumor burdens
present theoretical scalability challenges when translating findings
to human-scale practicality. To address these challenges we sought
to evaluate theoretical detection limits for our biomarker based on
an in vitro assay and detect small tumor burdens in vivo by 3
methods: IVIS luminescence imaging, virus-mediated GLuc
expression in serum and post-mortem histological analysis. The
blood volume in a mouse is approximately 2 mL (8% of the 25 g
total body weight [30]). Spherical SKNEP-Luc tumor comprised
of 10
6 cells was determined to be 1.83 mm in diameter by
measuring volume occupied in a centrifuged sample of an equal
number of cells, assuming small tumors are comprised predom-
inantly of tumor cells. Ten to 1 million cells were plated in 2 mL of
cell culture media and co-infected with rQ-M38G at an MOI of 3
to ensure every cell would be infected. Two days after infection cell
culture media was collected and analyzed for GLuc concentration.
Virus-mediated GLuc expression could be reliably resolved by
simultaneously transducing 1,000 cells, which approximates a
spherical tumor of diameter 183 microns (Fig. S9).
Ewings sarcoma tumors (SKNEP-Luc) of different sizes were
established in 11 mice by injecting 10
6 cells into the left kidney
subcapsularly in 3 groups of mice on 3 consecutive weeks. Mice
with tumors that had developed over 2, 3 and 4 weeks and 4
tumor-free control mice were infected systemically with 1610
7 pfu
of rQ-M38G. Four days following infection mice were imaged via
IVIS, blood samples collected for GLuc quantitation, and mice
were sacrificed for histological tumor sizing. In vivo imaging for
luciferase expression revealed mice baring tumors drastically
different in size at the time of infection and sacrifice (extreme
examples shown in Fig. 5a). Serum GLuc concentration in tumor
bearing mice 4 days after infection revealed GLuc levels greater
than similarly infected tumor-free control mice (Fig. 5b). Histo-
logical evaluation of tumors in each mouse revealed a macroscopic
tumor and microscopic tumor foci in mouse i and ii respectively
(Fig. 5c).
Discussion
We developed a novel cancer screening strategy whereby
tumors are forced to secrete a biomarker. We developed a
conditionally replicative HSV, rQ-M38G, to selectively force
tumor cells to secrete Gaussia luciferase as a demonstration of this
Figure 3. Detection of tumor presence by serum biomarker levels. (a) Time course of GLuc expression in renal subcapsule (r.s.c) SK-NEP_Luc-
bearing and tumor-free mice injected systemically with 1.2610
7 pfu or rQ-M38G. Numbers in legend represent individual mice. (b) GLuc expression
and in vivo imaging of SK-NEP_Luc-bearing mice four days following systemic injection of 1.2610
7 pfu of rQ-M38G. Serum GLuc levels for mice
injected with tumor and control that did not receive tumor injections (bar graph), and in vivo luciferase imaging of mice that received tumor cell
injections.
doi:10.1371/journal.pone.0019530.g003
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M38G expressed higher levels of biomarker compared with
tumor-free animals, which showed only low, background expres-
sion. The utility of rQM-38G for screening appeared to be a
function of the capability of a given tumor to support HSV
replication. Regardless of tumor type or location, tumor screening
by rQ-M38G was highly sensitive to tumor presence.
A critical feature for cancer screening is the ability to detect
small tumors, ultimately in people. One a priori concern was that
small tumors may be associated with less vascular surface area
available for HSV entry. This issue did not appear to be a
limitation in mice, because in some of the models we were able to
detect tumors as small as 4–5 mm in diameter (50 mm
3)a n di n
another model we detected microscopic tumor burden. Scal-
ability to humans (with larger blood volumes) is difficult to
predict, but some estimates are possible. In vitro evaluation of
increasing numbers of SKNEP-Luc tumor cells indicates that
infecting as few as 1,000 cells in a volume of cell culture media
equal to a mouse blood volume yields detectable GLuc secretion.
Therefore, simultaneous expression of GLuc from 1,000 cells at
any time in a mouse is theoretically detectable. Under these
conditions infecting 10% of the cells in a tumor of diameter
400 mm( 1 0
4 cells) would be detectable in a mouse. When scaled
from a mouse to a human the theoretical limit of detection is
increased by a ratio of 1:2600 (25 mg mouse:65 kg human) and
diluting the biomarker in a larger average human blood volume
of 4.7 L. Using these numbers, the theoretical limit of detection
when infecting 10% of the cells in a tumor is changed from a
394 um diameter mass in a mouse to a 1–4 mm tumor diameter
in a human. If only 1% of tumor cells are transduced by virus,
tumors as small as 8.5 mm in diameter might still be detectable
using these calculations. This sensitivity suggests strong potential
for identifying minimal tumor burdens even when scaled to
human proportions.
The ability of this screening strategy to reveal tumors is
dependent upon viral factors, tumor microenvironment, and
biomarker detection limitations each of which can be enhanced for
real world practicality. Here we employed a doubly attenuated
HSV to effect a tumor specific transduction and gene expression.
Such vectors have already been documented to be safe for human
use [31]. Alternative viruses with single or less-attenuating
mutations demonstrate greater oncolytic capacity are also already
in clinical trials (e.g., HSV1716, see www.clinicaltr als.gov,
NCT00931931). Coupling this screening strategy to less attenu-
ated viruses will likely diversify its utility among the various solid
malignancies as well as enhance the therapeutic component.
Agents that are simultaneously both diagnostic and therapeutic
have been dubbed ‘‘theragnostic.’’ It is possible our strategy could
be further refined by the use of a more robust cancer-dependent
promoter to drive biomarker expression. Improved vector delivery
to the tumor may also be achieved using tumor targeting small
molecule and nanoparticles uptake-enhancement strategies as
recently described with the use of internalizing RGD peptides [8].
Eventual commercialization of our proposed screening strategy
would benefit from using biomarkers that are already in
widespread use such as bHCG (pregnancy test), PSA (prostate
cancer) and aFP (liver and germ cell malignancies). Biomarker
assay sensitivity in the context of this screening strategy can still
Figure 4. Virus biodistribution. (a) GFP immunofluoresence in SK-NEP_Luc-bearing mice with and without systemic virus administration. Mice
receiving virus (#1 and #2) showed selective GFP expression in tumor, while mice receiving no virus (No Virus Control) showed global GFP-
negativity. Scale bar=15 microns. (b) Biodistribution of virus in mice with SK-NEP_Luc tumors following systemic administration as determined by
qPCR for viral genomes.
doi:10.1371/journal.pone.0019530.g004
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iimprove exponentially as is being realized with microfluidic
technologies [32,33,34,35].
A significant concern for the prototypical cancer screening
method developed in this work is the development of an immune
response to the gene delivery agent or the transduced biomarker
that would preclude repeated use of the screening tool. Previous
work in the field has shown that pre-immunized animals still
experience therapeutic benefit from HSV with sustained efficacy
[36]. Because 80% of the general population has been exposed to
HSV, implementing this detection strategy with HSV will depend
upon the efficacy of engineered HSVs administered to immuno-
competent subjects who have previously been exposed to wild-type
HSV strains. In vitro screening for mouse tumor cell lines revealed
that all mouse lines we tested exhibited comparably low
susceptibility to infection by our attenuated mutant virus, on par
with normal quiescent human cells. In vivo models of HGF116
demonstrated no virus sensitivity following i.t. or i.v. injection.
Thus, we are unable to assess our cancer screening strategy in an
immunocompetent model until the identification of mouse models
that are more susceptible to human HSV. Implementation of this
strategy may evolve with non-viral vectors [37] or viral vectors
masked in liposomes [38].
The challenge of population-wide cancer screening is the
development of clinical assays that are fiscally practical, universal
across a spectrum of cancer types, and easy to implement. Physical
examination, while affordable, often fails to identify malignancies
that are deep or asymptomatic. Imaging benefits from high
sensitivity, but may not always differentiate nonspecific or benign
masses from malignant disease (eg, lung nodules may be granuloma
or cancer), is financially challenging and difficult to broadly
implement. With the identification of appropriate biomarkers,
cancer screening could potentially be economically viable with
automated point of care testing (POCT) technologies (www.i-stat.
com, www.biosite.com, www.siloambio.com [39]).
This work demonstrates the principle of inducing expression of
a secretable transgene in cancer using a systemically administered
gene delivery agent as a biomarker to screen for tumor presence.
The novel screening principle proposed and demonstrated in this
work could hold immediate implications for patients with known
cancer risks such as genetic predispositions (BRCA-1, Nf1
mutations) or patients with a history of cancer who are at high
risk for recurrence. Ultimately, exogenous administration of a
cancer targeting gene delivery agent (infectious or not) could force
any malignancy to secrete a biomarker and could be used as a
universal first step for population-wide cancer screening. The
impact of this approach would revolutionize the technology for
cancer detection in industrialized nations and the developing




Human tumor cell lines have been described previously [40,41]
or were purchased from American Type Culture Collection
(ATCC, Manassas, VA) except SK-NEP_Luc, which was a kind
gift from Jason Frischer (CCHMC, Cincinnati, OH). Cells were
grown in DMEM or McCoys 5A medium (ATCC, SK-OV-3,
Figure 5. Sensitivity limits of detection. a) in vivo imaging of two mice (i and ii) with vastly different SKNEP-Luc tumor burdens. b) Serum GLuc
concentration in mouse i, ii and four tumor-free control mice 4 days following systemic infection with 1610
7 pfu of rQ-M38G. c) Hematoxylin and
eosin macroscopic images of tumor bearing kidneys (T=tumor, scale bars=1 mm) and insets of microscopic tumor foci in the renal parenchyma of
mouse ii (scale bar=200 mm).
doi:10.1371/journal.pone.0019530.g005
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and penicillin/streptomycin (Life Technologies, Carlsbad, CA).
Mouse C57/Bl6 cell lines LLC
GFP [42] (Lewis lung carcinoma)
and B16-BL6 (melanoma) were kind gifts from Joe Palumbo
(CCHMC, Cincinnati, OH) and HGF116 (rhabdomyosarcoma)
was derived from a genetically engineered mouse. Primary human
foreskin keratinocytes (HFK) were a kind gift from Susa Wells
(CCHMC, Cincinnati, OH), grown in EpiLife Media (Cascade
Biologics, Portland, OR) and differentiated into quiescent
keratinocytes with 10% FBS and 1 mmol/L CaCl2 [43].
rQ-M38G was constructed as follows: The UL38 promotor was
isolatedfromHSVrRp450byPCRusingprimersdesignedpreviously
[18] that were modified to include a 59 BglII and 39 HindIII sites (F1,
R1inTableS1)andclonedintotheBglIIandHindIIIsitesofpCMV-
GLuc (Invitrogen), replacing the CMV promoter. The UL38p-GLuc
cassettewasamplifiedbyPCRfrompUL38p-GLucwithinclusionofa
59SpeI and 39 EcoRI and cloned into the SpeI-EcoRI sites of the
‘‘HSV-Quick’’ shuttle plasmid, pT-OriSIE4/5 [29] (a kind gift from
Yoshinaga Saeki, The Ohio State University, Columbus, Ohio), in
whichtheoriS(E4/5KpnIfragmenthadbeenremoved.Theresulting
plasmid,pT-UL38p-GLuc,wasusedintheHSVQuickBACsystemto
generate rQ-M38G [29]. Primers for PCR analysis and sequencing
a r es h o w ni nT a b l eS 2 .V i r u s e sw e r ep r o p a g a t e da n dt i t e r e d[ 4 4 ]b y
plaqueassayonVerocells.Cellcytotoxicitywasdeterminedin96-well
tissue culture plates using a modified MTS/PMS assay (Promega,
Madison, WI).
Gaussia luciferase assay
GLuc activity was assessed on 10 mL samples of tissue culture
media or serum by chemiluminescent assay [45] on an autoin-
jecting luminometer by injecting 50 mLo f5 0mM coelenterazine
(Prolume, Pinetop, AZ) to each sample in triplicate and integrating
the signal for 2.5 seconds [26].
Virus biodistribution
Animal studies were approved by the Cincinnati Children’s
Hospital Institutional Animal Care and Use Committee (Animal
protocol #9D12095). 5–6-week old female Balb/c athymic nude
mice (Harlan Sprague Dawley, Indianapolis, IN) were injected with
1–5 million cells. Cells were prepared in 33% Matrigel (Becton
Dickinson, Bedford, MA) and 66% phosphate buffered saline (PBS,
pH 7.4) for subcutaneous (s.q.) injection and PBS only for renal
subcapsule (r.s.c) or intraperitoneal (i.p.) injection. Virus doses are
described in the text. Virus was suspended in 100–150 mL of PBS for
tail vein injections and 50–100 mL of PBS for intratumoral injections,
which were distributed into 5 fractions throughout the tumor.
Tissue preparation and immunofluorescence
Tissues were fixed, embedded, and cut into 12-micron sections
using standard procedures. Sections were permeablized with 0.2%
Triton-X in PBS for 10 minutes, blocked in 10% normal goat
serum for 60–90 minutes, and incubated with Chicken anti-GFP
(#16901, Millipore/Chemicon, Billerica, MA) for 60 minutes,
rinsed three times with PBS, and incubated with secondary
antibody (Goat anti-Chicken FITC, Jackson ImmunoResearch,
West Grove, PA), rinsed with PBS, and mounted with Fluor-
omount-G (Electron Microscopy Sciences, Hatfield, PA). All slides
were then imaged with OpenLab Imaging Software (Improvision,
Waltham, MA) on an inverted fluorescent Zeiss microscope.
HSV genome quantitation
DNA was isolated from mouse tissues using the Gentra
Puregene DNA isolation kit (Qiagen, Valencia, CA) and quantified
using the NanoDrop 2000 spectrophotometer (Thermo Scientific,
Wilmington, DE). Real-time PCR was performed using the ABI
7500 system (Applied Biosystem, Foster City, CA) [46]. Standards
were made from purified HSV1716 viral DNA.
rQ-M38G gene expression and replication studies in cell
lines
Cells were infected in 12-well dishes for 1 hour and harvested at
times indicated. 100 uL of the cell suspension was used for
measuring Gaussia luciferase, while the remaining cell suspension
was subjected to three cycles of freeze–thaw and centrifuged at
20,0006 g. Pellets were resuspended in 200 uL PBS. DNA was
isolated using the DNeasy Blood and Tissue kit (Qiagen, Valencia,
CA). Fast real-time PCR was performed using the 7900HT Fast
Real Time PCR System (Applied Biosystem, Foster City, CA).
Standard DNA or DNA extracted from infected cells (40 ng) was
added to 10 mL of SYBR Premix Ex Taq II Kit (TaKaRa, Otsu,
Shiga, Japan), 1.6 mL of a thymidine kinase primer mixture (TK
290-F: 59 TCG CGA ACA TCT ACA CCA CAC AAC; TK 400-
R: 59 CGG CAT AAG GCA TGC CCA TTG TTA; each at
400 nM), 0.4 mL Rox (TaKaRa) and PCR-grade water to a final
volume of 20 ml per reaction. PCR was 1 cycle of 95uC for
30 seconds, 40 cycles of 95uC for 3 seconds, 60uC for 15 seconds,
and 72uC for 25 seconds.
In vivo imaging
Mice were injected i.p. with 150 mg/kg of D-luciferin (Caliper
Life Sciences, Hopkinton, MA) and imaged by IVIS200 (Calipur
Lifesciences).
Supporting Information
Figure S1 GLuc excretion following infection of Vero cells and
4 human tumor cell lines (100,000 cells/well) with rQ-M38G
across a range of MOIs.
(TIF)
Figure S2 Virus replication as measured by qPCR following
infection of Vero cells and 4 human tumor cell lines (100,000
cells/well) with rQ-M38G across a range of MOIs.
(TIF)
Figure S3 In vitro cytotoxicity of rQ-M38G in a well
characterized virus permissive cell line (Vero), replicating and
non-replicating human keratinocytes (HFK-r and HFK-q respec-
tively), 5 human tumor cell lines (S462.TY, Osteomet, SK-OV-3,




Figure S4 Serum GLuc levels following i.v. infection with
1610
7 pfu of rQ-M38G in mice bearing intraperitoneal, intra-
muscular and subcutaneous tumors.
(TIF)
Figure S5 GLuc expression in two MPNST tumor models
(S462.TY and STS26T_dsRed) with low in vitro virus sensitivity
and GFP expression in S462.TY-bearing mice. (a) Serum GLuc
following systemic injection of 5610
7 pfu of rQ-M38G by tail vein
into mice bearing S462.TY subcutaneous tumors. Shaded gray
represent the range of GLuc levels for tumor-free mice which
received the same dose of virus; (b) Serum GLuc levels following
systemic administration of 1610
7 pfu of rQ-M38G in mice
bearing subcutaneous STS26T_dsRed tumors; and (c) GFP
expression in 2 S462.TY-bearing mice (#iii and #vii) demon-
strating few punctate GFP positive cells in tumors and no GFP
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3) at time of
virus injection is noted for each mouse in the plot legends.
(TIF)
Figure S6 Serum GLuc levels following systemic administration
of 1610
7 pfu of rQ-M38G in mice which were injected with
2610
6 STS26T_dsRed cells intraperitoneally.
(TIF)
Figure S7 Serum GLuc levels (a), and number of virus copies in
tumors as determined by qPCR (b) following direct intratumoral
injection of rQ-M38G into subcutaneous Osteomet tumors larger
than 200 mm
3. c) Serum GLuc levels in a subcutaneous in vivo
model for Osteomet following systemic injection of 1.9610
7 pfu or
1.9610
5 pfu of rQ-M38G. Gray shaded area represents serum
GLuc levels in tumor free mice also receiving 1.9610
7 pfu of rQ-
M38G. Key identifies mouse number, virus dose, and tumor size
at time of injection respectively.
(TIF)
Figure S8 Serum GLuc levels from S462.TY bearing mice four
days following i.t. injection of 8610
3 pfu or 8610
7 pfu of rQ-M38G.
(TIF)
Figure S9 In vitro modeling of increasing numbers of cells
(SKNEP-Luc), their theoretical tumor volume and GLuc produc-
tion from infection of every cell.
(TIF)
Table S1 Primers used in the production of HSV-UL38p-GLuc
(rQ-M38G).
(TIFF)
Table S2 UL38-GLuc sequence.
(TIFF)
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